REBECCA, stands for REsearch on BrEast Cancer induced chronic conditions supported by Causal Analysis of multi-source data, project aims to tap into the potential of Real-World Data to support clinical research and to improve existing clinical workflows.
REBECCA will combine clinical data with data describing patients’ real-life behaviour including physical activity, eating habits, sleep and online interactions. These new forms of Real-World Data will be collected via mobile and wearable devices.
Novel functional and emotional indices will be produced for each individual and used to examine patient status and quality of life. REBECCA will use these indices for optimising patient care and as complementary outcomes during clinical research.
REBECCA 360º platform, a combination of minimally obtrusive, non-stigmatising mobile applications, will be offered to breast cancer survivors as a means of supporting their everyday life and enhancing their interaction with health experts. The platform will be deployed within 7 clinical studies in 3 countries, Norway, Spain, and Sweden, involving over 650 individuals, and it will help shape future guidelines and practices for post-cancer treatment. Best practices resulting from the studies will be disseminated to researchers, public health and regulatory bodies throughout Europe.
Real-World Data in Clinical Research
Clinical research is undergoing a revolutionary transformation. The emergence of Electronic Health Records (EHR) and digital registries and the widespread use of smartphones and wearable devices have led to an increasing amount of health and lifestyle data that can be continuously collected for each patient. Such Real-World Data (RWD) present a major opportunity for advancing clinical research. Yet, to this data, this opportunity remains largely untapped.Find Out More
REBECCA aims to tap into the potential of Real-World Data (RWD), combining it with an advanced data management platform and innovative causal data modelling methodologies, to improve clinical research on Complex Chronic Conditions (CCC) and to improve the healthcare outcomes for patients who have undergone or are still in primary cancer treatment. To realise its Research and Innovation mission, over the course of 4 years REBECCA will pursue the following objectives.Find Out More
REBECCA brings together 12 partners from 7 European countries, and is led by the Aristotle University of Thessaloniki.
REBCCA Consortium consists of clinical and technological universities, industry leaders, public health experts, and patient associations who will work together over the course of 4 years to shape guidelines and practices for post-cancer treatment.Find Out More
Have a question? Why not view our frequently asked questions page
and find out more about the project.